Ignite Creation Date:
2025-12-25 @ 2:28 AM
Ignite Modification Date:
2026-02-28 @ 7:10 PM
Study NCT ID:
NCT01777334
Status:
COMPLETED
Last Update Posted:
2018-01-24
First Post:
2013-01-24
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-01-23
Start Date Type:
ACTUAL
Primary Completion Date:
2013-09-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-09-24
Completion Date Type:
ACTUAL
First Submit Date:
2013-01-24
First Submit QC Date:
None
Study First Post Date:
2013-01-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-04-24
Results First Submit QC Date:
None
Results First Post Date:
2014-06-05
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-01-18
Last Update Post Date:
2018-01-24
Last Update Post Date Type:
ACTUAL